RT Journal Article
SR Electronic
T1 Risk of Severe COVID–19 Outcomes Among Patients with Rheumatoid Arthritis in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.09.21260106
DO 10.1101/2021.07.09.21260106
A1 Ching-Yi Chuo
A1 Vince Yau
A1 Sriraman Madhavan
A1 Larry Tsai
A1 Jenny Chia
YR 2021
UL http://medrxiv.org/content/early/2021/07/12/2021.07.09.21260106.abstract
AB Introduction Coronavirus disease 2019 (COVID–19) has infected over 22 million individuals worldwide. It remains unclear whether patients with COVID–19 and Rheumatoid Arthritis (RA) experience worse clinical outcomes compared to similar patients with COVID–19 without RA.Aim The aim of this study is to provide insights on how COVID–19 impacted patients with RA given the nature of the disease and medication used.Methods RA cases were identified via International Classification of Diseases (ICD) codes and COVID–19 cases by laboratory results in the U.S. based TriNetX network. Patients with COVID–19 and RA were propensity–score matched based on demographics with patients with COVID–19 without RA at a 1:3 ratio. A hospitalized sub-population was defined by procedure codes.Results We identified 1,014 COVID-19 patients with RA and 3,042 non-RA matches selected from 137,757 patients. The odds of hospitalization (non-RA:23%, RA:24.6%, OR:1.08, 95% CI: 0.88 to 1.33) or mortality (non-RA:5.4%, RA:6%, OR:0.93, 95% CI: 0.65 to 1.34) were not significantly different.The hospitalized sub-population included 249 patients with COVID-19 and RA and 745 non-RA matches selected from 21,435 patients. The risk of intensive care unit (ICU) admission (non-RA:18.8%, RA:18.1%, OR:0.94, 95% CI: 0.60 to 1.45), and inpatient mortality (non-RA:14.4%, RA:14.5%, OR:0.86, 95% CI: 0.53 to 1.40) were not significantly different.Conclusion We didn’t find evidence suggesting patients with COVID–19 and RA are more likely to have severe outcomes than patients with COVID–19 without RA.Key Messages– Patients with Rheumatoid Arthritis (RA) tend to be older, and often have co-morbidities which could put them at greater risk of severe COVID-19 outcomes.– This study is one of the largest studies of COVID-19 infected RA populations to date. We did not find increased risk of hospitalization, ICU admission, or mortality among RA patients vs. matched non-RA patients.– Patients previously exposed to anti-coagulants experienced higher risks of hospitalization and overall mortality. Extra attention is needed for treating such patients.Competing Interest StatementAll authors on this paper are employed by Genentech, which is a member of the Roche Group.Funding StatementThis study was funded by GenentechAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Western Institutional Review Board reviewed the use of TrinetX COVID-19 data and has granted a waiver because of its deidentified nature and no human subject involvement. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe are not providing the patient-level data per TriNetX's policy. TriNetX maintains processes and procedures to respond to questions about the data. If editors or reviewers have questions about TriNetX data, TriNetX provides details on the data provenance and/or the necessary access to audit the processes. If the validity of the data is questioned further, TriNetX would make the data available for a third party audit.